Galmed Pharmaceuticals (NASDAQ:GLMD) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report released on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Performance

Shares of Galmed Pharmaceuticals stock opened at $1.73 on Wednesday. The business has a 50-day simple moving average of $2.54 and a 200-day simple moving average of $3.45. The company has a market cap of $1.11 million, a PE ratio of -0.10 and a beta of 0.72. Galmed Pharmaceuticals has a one year low of $1.67 and a one year high of $23.80.

Hedge Funds Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC purchased a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned approximately 3.97% of Galmed Pharmaceuticals as of its most recent SEC filing. 76.14% of the stock is owned by institutional investors and hedge funds.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.